Compositions and methods for diagnosing and treating Sjogren's Syndrome
Methods for detection and diagnosis of Sjögren's Syndrome in a subject, determining the stage or progression of Sjögren's Syndrome in a subject, determining the effectiveness of a treatment for Sjögren's Syndrome, and selecting a subject for treatment for Sjögren's Syndrome are disclosed. The methods typically include measuring the level of one or more Sjögren's Syndrome biomarkers in a biological sample obtained from a subject. Biomarkers for Sjögren's Syndrome include, but are not limited to, GADD153 and Del-1.
1. A method of diagnosing and treating one or more symptoms of Sjögren's Syndrome in a subject comprising:
measuring the level of growth arrest and DNA damage-inducible protein GADD153 (GADD153) and developmental endothelial locus-1 Del-1 (Del-1) in a biological sample obtained from the subject and comparing it to a control,
wherein the biological sample is selected from the group consisting of tears, saliva, salivary gland tissue, blood, serum, and plasma,
wherein an increase in GADD153 expression in the biological sample of the subject and a decrease in Del-1 expression in the biological sample of the subject compared to the control is indicative that the subject has Sjögren's Syndrome; and
administering one or more therapeutic compositions selected from the group consisting of saliva substitutes, saliva stimulants, interferon-alpha, artificial tears, methylcellulose inserts, eye ointments, muscarinic agonist drugs, immunomodulatory drugs, and autologous serum drops in an amount effective to treat one or more symptoms of Sjögren's Syndrome in the subject having gren's Syndrome.
2. The method of claim 1 , further comprising the step of measuring the amount of interleukin-10 in the salivary glands of the subject, wherein a statistically significant reduction of IL-10 in the salivary glands of the subject is indicative that the subject has Sjögren's Syndrome.
3. The method of claim 1 , further comprising the step of measuring the amount of interleukin-17 (IL-17) in the salivary glands of the subject, wherein a statistically significant increase in IL-17 in the salivary glands of the subject is indicative that the subject has Sjögren's Syndrome.
4. The method of claim 1 , further comprising the step of detecting a disruption in ψ m in association with a statistically significant increase in both apoptosis and necrosis accompanied by caspase 3 activation, wherein a disruption in ψ m in association with a statistically significant increase in both apoptosis and necrosis accompanied by caspase 3 activation is indicative that the subject has Sjögren's Syndrome.
5. A method of diagnosing and treating one or more symptoms of Sjögren's Syndrome in a subject comprising:
assaying a biological sample obtained from the subject for:
(a) levels of GADD153, Del-1, IL-10, IL-17 and disruption in ψ m in association with a statistically significant increase in both apoptosis and necrosis accompanied by caspase 3activation in the biological sample of the subject, wherein
(1) a statistically significant decrease in Del-1,
(2) a statistically significant increase in GADD153,
(3) a statistically significant reduction of IL-10,
(4) a statistically significant increase in IL-17, and
(5) a disruption in ψ m in association with a statistically significant increase in both apoptosis and necrosis accompanied by caspase 3 activation
compared to the control is indicative that the subject has Sjögren's Syndrome, wherein the biological sample is selected from the group consisting of tears, saliva, salivary gland tissue, blood, serum, and plasma;
and administering and effective amount of Del-1 to treat one or more symptoms of Sjögren's Syndrome in the subject having Sjögren's Syndrome.